Company: SUPN
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001356576-25-000071
Chunk: 101

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 1
Chunk 101
---
 Excludes amortization of intangible assets

See accompanying notes.

4

Table of Contents

Supernus Pharmaceuticals, Inc.

Condensed Consolidated Statements of Comprehensive Earnings (Loss)

(in thousands)

Three Months EndedSeptember 30,Nine Months EndedSeptember 30,2025202420252024(unaudited)(unaudited)Net earnings (loss)$(45,117)$38,497 $(34,445)$58,537 Other comprehensive gain (loss)Unrealized gain (loss) on marketable securities, net of tax129 450 118 671 Other comprehensive gain (loss)129 450 118 671 Comprehensive earnings (loss)$(44,988)$38,947 $(34,327)$59,208 

See accompanying notes.

5

Supernus Pharmaceuticals, Inc.

Condensed Consolidated Statements of Changes in Stockholders' Equity 

(unaudited, in thousands, except share data)

jCommon StockAdditional Paid-in CapitalAccumulated OtherComprehensiveEarnings (Loss)RetainedEarningsTotalStockholders'EquitySharesAmountBalance, December 31, 202455,743,095 $56 $479,440 $(189)$556,426 $1,035,733 Share-based compensation expense related to employee stock purchase plan and share-based awards— — 8,068 — — 8,068 Issuance of common stock related to employee stock purchase plan and share-based awards, net of taxes withheld246,153 — (1,299)— — (1,299)Net loss— — — — (11,827)(11,827)Unrealized gain on marketable securities, net of tax— — — 30 — 30 Balance, March 31, 202555,989,248 56 486,209 (159)544,599 1,030,705 Share-based compensation expense related to employee stock purchase plan and share-based awards— 7,507 — — 7,507 Issuance of common stock related to employee stock purchase plan and share-based awards, net of taxes withheld130,112 — 3,230 — — 3,230 Net earnings— — — — 22,499 22,499 Unrealized loss on marketable securities, net of